The fallout from President Trump's tariff announcements and revisions hasn't yet pushed investors to shy away from an old habit: buying the dip. Data from VandaTrack showed the week following ...

Despite suffering a series of rebuffs from the FDA, Vanda Pharmaceuticals is continuing to fight for sedative Hetlioz, suing the regulator last week to use the drug off-label for jet lag. In the ...

After years of back-and-forth with the FDA over Hetlioz's potential use as a jet lag disorder treatment, Vanda Pharmaceuticals is pursuing a new route to establish the drug in the space.

Vanda trades at a discount despite strong revenue and cash exceeding its market cap, with no debt and substantial sales. The company has three approved products: HETLIOZ, FANAPT, and PONVORY, with ...

Vanda has previously published an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S." In addition to the data published in the article, this poster ...

Bár utána elmondása szerint azóta megbánta, hogy borította a bilit, most újabb haragost szerzett magának. Schumacher Vanda neve is felmerült abban a bizonyos beszélgetésben, ő pedig ezen elképesztően ...

The latest price target for Vanda Pharmaceuticals (NASDAQ:VNDA) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $20.00 expecting VNDA to rise to ...

How many apartments are listed for sale in Orchidea Residence? On Bayut, the number of currently listed flats to buy in Orchidea Residence is 5. How much do the prices of an apartment for sale vary in ...